Expert InterviewBIIB
Slingshot members are talking to an expert! The topic is:
Examining the Phase 3 TRAILBLAZER-ALZ 2 LTE results for Kisunla (donanemab-azbt) and subcutaneous maintenance dosing data for Leqembi (lecanemab-irmb) in early Alzheimer’s disease
Executed on:Sep 16, 2025 7:30 AM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Maryland Center of Neurology and Sleep
- Board Certified neurologist at Maryland Center of Neurology and Sleep
- Treats 50 patients with Alzheimer's Disease and 500 patients with Multiple Sclerosis
- Clinical interest in Alzheimer's Disease, multiple sclerosis and transverse myelitis management
Interview Goal
The interview aims to explore new data on amyloid-targeting therapies in Alzheimer’s disease presented at AAIC 2025. Discussion will focus on the long-term extension (LTE) of Lilly’s Phase 3 TRAILBLAZER-ALZ 2 study showing sustained and growing benefit of Kisunla (donanemab-azbt) over three years, as well as Eisai and Biogen’s investigational subcutaneous autoinjector of Leqembi (lecanemab-irmb) as a maintenance option. The conversation will address comparative efficacy, safety, convenience, and the evolving treatment paradigm for early Alzheimer’s disease.